Research programme: small molecule therapeutics - Nimbus TherapeuticsAlternative Names: NDI-031232; NDI-031301; NDI-031302
Latest Information Update: 24 Jan 2017
At a glance
- Originator Nimbus Therapeutics
- Class Small molecules
- Mechanism of Action Interferon inhibitors; Interferon receptor agonists; KRAS protein inhibitors; TYK2 kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Inflammation